140 related articles for article (PubMed ID: 24641768)
1. Could immunosignatures technology enable the development of a preventative cancer vaccine?
Shen L; Hansen DT; Johnston SA; Legutki JB
Expert Rev Vaccines; 2014 May; 13(5):577-9. PubMed ID: 24641768
[TBL] [Abstract][Full Text] [Related]
2. MUC1 as a target antigen for cancer immunotherapy.
Acres B; Limacher JM
Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
[TBL] [Abstract][Full Text] [Related]
3. Cell based cancer vaccines: regulatory and commercial development.
Copier J; Ward S; Dalgleish A
Vaccine; 2007 Sep; 25 Suppl 2():B35-46. PubMed ID: 17916462
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines.
Dalgleish AG
Br J Cancer; 2000 May; 82(10):1619-24. PubMed ID: 10817493
[No Abstract] [Full Text] [Related]
5. Design of clinical trials for therapeutic cancer vaccines development.
Mackiewicz J; Mackiewicz A
Eur J Pharmacol; 2009 Dec; 625(1-3):84-9. PubMed ID: 19835869
[TBL] [Abstract][Full Text] [Related]
6. Cancer vaccines and immunotherapies: emerging perspectives.
Henderson RA; Mossman S; Nairn N; Cheever MA
Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
[TBL] [Abstract][Full Text] [Related]
7. The case for polyvalent cancer vaccines that induce antibodies.
Ragupathi G; Livingston P
Expert Rev Vaccines; 2002 Aug; 1(2):193-206. PubMed ID: 12901558
[TBL] [Abstract][Full Text] [Related]
8. [Current status and future perspective of cancer vaccine development].
Sasada T; Itoh K
Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
[TBL] [Abstract][Full Text] [Related]
9. Cancer vaccines: a step towards prevention and treatment of cancer.
Pandey M; Mathew A; Nair MK
Eur J Surg Oncol; 1999 Apr; 25(2):209-14. PubMed ID: 10218468
[TBL] [Abstract][Full Text] [Related]
10. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
12. Cellular and humoral immune responses of cancer patients to defined tumor antigens.
Jäger D; Jäger E; Bert F; Knuth A
Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025
[No Abstract] [Full Text] [Related]
13. Current developments with peptide-based human tumor vaccines.
Khazaie K; Bonertz A; Beckhove P
Curr Opin Oncol; 2009 Nov; 21(6):524-30. PubMed ID: 19770763
[TBL] [Abstract][Full Text] [Related]
14. Promising particle-based vaccines in cancer therapy.
Xiang SD; Scalzo-Inguanti K; Minigo G; Park A; Hardy CL; Plebanski M
Expert Rev Vaccines; 2008 Sep; 7(7):1103-19. PubMed ID: 18767957
[TBL] [Abstract][Full Text] [Related]
15. [Oncoimmunology: some fundamental problems of cancer immunotherapy].
Nedospasov SA; Kuprash DV
Mol Biol (Mosk); 2007; 41(2):355-68. PubMed ID: 17514902
[TBL] [Abstract][Full Text] [Related]
16. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
Nelson B
Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
[No Abstract] [Full Text] [Related]
17. Interpreting cancer vaccine clinical trials.
Dranoff G
J Gene Med; 1999; 1(2):80-3. PubMed ID: 10738571
[TBL] [Abstract][Full Text] [Related]
18. Cancer vaccines.
Liu MA
Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2823-6. PubMed ID: 21893546
[TBL] [Abstract][Full Text] [Related]
19. New approaches to immunoprevention and immunotherapy of neoplasms.
Glushkov AN
Russ J Immunol; 2002 Oct; 7(3):219-28. PubMed ID: 12674931
[TBL] [Abstract][Full Text] [Related]
20. Advances in prophylactic cancer vaccine research.
Le Poole IC; Bommiasamy H; Bocchetta M; Kast WM
Expert Rev Anticancer Ther; 2003 Aug; 3(4):537-45. PubMed ID: 12934665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
